A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3
1438-0003
Phase 1 other active
Quick answer
A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3 for Glioma expressing DLL3 is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Glioma expressing DLL3
- Phase
- Phase 1
- Modality
- other
- Status
- active